Comprehensive study of an implantable total artificial heart using continuous flow blood pump

全人工心脏（TAH）有望成为心脏替代的终极器械。为了开发高性能的小型植入式TAH，对波动泵TAH进行了改进，并开发了下一代TAH螺旋流TAH（HFTAH）。将新开发的HFTAH植入山羊体内，通过提供TAH的生理控制方法1/R控制，获得了100天的最大存活。在无搏动型TAH的平板运动实验中，搏动型TAH与无搏动型TAH之间无明显差异。为了开发一种植入式控制器，植入式压力传感器（IPS）的校准方法和使用IPS的平均心房压力的估计逻辑进行。为了提高器械部件的生物相容性，开发了人工材料与生物材料融合构建的混杂部件。

The total artificial heart (TAH) is expected to be an ultimate device for heart replacement. To develop small-size implantable TAH with high performance, improvement of the undulation pump TAH and development of the helical flow TAH (HFTAH) that is a next generation TAH were performed. The newly developed HFTAH was implanted in goats and 100 days of maximum survival was obtained by providing 1/R control that is a physiological control method of the TAH. In the experiment of treadmill exercise with the nonpulsatile TAH, there found no obvious difference between pulsatile and nonpulsatile TAHs. To develop an implantable controller, calibration method of implantable pressure sensor (IPS) and estimation logic of mean atrial pressure using IPS were performed. To improve biological compatibility of device parts, the hybrid parts constructed with fusion of artificial material and biological material were developed.